One more potential Teva-related challenge for Mylan's shareholders: A huge tax bill

Shareholders could be forced to foot a big bill for short-term capital gain taxes if a deal closes before the end of February 2016.

By Nicole Gray • May 15, 2015

Sanofi moving forward on Celiac disease immunotherapy development

The French pharma giant has a collaborative partnership with Selecta Biosciences.

By Nicole Gray • May 14, 2015

Glaxo CEO skeptical about pharma's M&A frenzy

Andrew Witty feels the industry's "deal rush" is fueled by cheap money, rather than the true value of acquisitions.

By Nicole Gray • May 13, 2015

HIV cure, not just treatment, is goal of Glaxo-UNC partnership

Academic and pharmaceutical researchers will work side-by-side on potential therapies to cure the virus.

By Nicole Gray • May 12, 2015

Mylan chairman thinks Teva a bad cultural fit, would consider buying it anyway

There's some mixed messaging coming from Robert Coury.

By Sy Mukherjee • May 11, 2015

M&A mayhem: Q1 biopharma deal values surpass 2014's total

There's been more than $166 billion in life sciences deals so far this year.

By Nicole Gray • May 8, 2015

Alexion to buy Synageva BioPharma in $8.4B rare disease megadeal

The deal values Synageva at more than double its Tuesday closing price.

By Sy Mukherjee • May 6, 2015

Bayer buys rights to Isis anti-clotting drug in $155M deal

The company's goal is to bolster its cardiovascular (CVD) franchise, which includes Xarelto, a novel oral anticoagulant.

By Nicole Gray • May 5, 2015

Pfizer emerges as mystery bidder for rare disease firm Swedish Orphan

Biogen and Investor AB were also considered contenders for acquisition of Swedish Orphan Biovitrum AB, also known as Sobi. 

By Nicole Gray • May 1, 2015

Perrigo rejects Mylan's third takeover offer

The company contends that when everything is factored in, Mylan's last two offers have been lower than the original $205 per-share offer.​

By Nicole Gray • April 30, 2015

Rare disease firm Swedish Orphan flies on mystery takeover offer

But the company's staying mum on who it is.

By Nicole Gray • April 27, 2015

A tale of 2 takeover bids: Teva-Mylan-Perrigo M&A drama goes hostile

Teva is pursuing Mylan while Mylan pursues Perrigo, and no one seems particularly interested in striking a deal.

By Nicole Gray • April 27, 2015

Novartis chief: We're actively looking for $2-$5 billion acquisitions

Which companies might get snatched up by the pharma giant?

By Nicole Gray • April 24, 2015

What biopharma needs to know about CAR-T cancer therapies

Pharmaceutical companies, government agencies, and high profile advocacy groups are developing collaborative alliances to unlock the potent therapeutic potential of CAR-T.

By Nicole Gray • April 24, 2015

Abbott's Mylan deal paying off big as M&A speculation sends shares soaring

Mylan shares have climbed more than 28% in the last three months.

By Nicole Gray • April 23, 2015

Bernstein analyst to Gilead: 'Pull the trigger' and buy Vertex

Geoffrey Porges believes that the "inevitable decline" of Gilead's HIV and hepatitis C franchises can be offset with the right acquisition. 

By Nicole Gray • April 22, 2015

UPDATE: Teva scores a takeover talking point as Perrigo board rejects Mylan bid

In a statement, Perrigo's board said that Mylan's $29 billion bid "substantially undervalues" the firm. Advantage: Teva.

By Nicole Gray • April 21, 2015

What a Celgene stake in Mesoblast means for the stem cell firm's prospects

Celgene's purchase of 15.3 million shares of Mesoblast at $3.82 per share has substantially increased investor confidence.

By Nicole Gray • April 14, 2015

Ichor, J&J to collaborate in $85M hep B immunotherapy deal

The two companies are working together to develop and commercialize DNA-based vaccine therapies for treatment of chronic hepatitis B using Ichtor's platform.

By Nicole Gray • April 14, 2015

Mylan's $29B Perrigo bid seen as defensive play against M&A threat

Analysts suspect that the company's offer was a defense against a Teva takeover. 

By Nicole Gray • April 13, 2015

UPDATE: Mylan offers $29 billion to buy Perrigo, create generics powerhouse

The offer amounts to $205 per share, or about a 24% premium over Perrigo's closing price on Tuesday.

By Sy Mukherjee • April 8, 2015

Targacept merger in jeopardy as Pfizer ends deal with buyer Catalyst

Targacept's stock has crashed hard on the news.

By Nicole Gray • April 7, 2015

MorphoSys CEO stays bullish on cancer drug despite Celgene split

The company plans to move forward with the development of MOR202. 

By Nicole Gray • April 7, 2015

Juno, Novartis settle cancer patent spat for $12 million

Novartis will end up paying Juno Therapeutics a total of $12.25 million plus milestones for use of its chimeric receptor technology. 

By Nicole Gray • April 7, 2015

4 big biopharma deals we might see in 2015

Biopharma's already off to a historic start when it comes to deals in 2015. Here are four other ones we might see this year.

By Sy Mukherjee • April 6, 2015